NASDAQ · TVGN
Healthcare · Biotechnology
$7.51
Up+$0.15 (+2.04%)
Updated Sep 15, 2026, 10:47 AM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
TVGN closed at $7.51 after 20 trading sessions, up 14.13% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 14, 2026 | $7.12 | $7.85 | $7.12 | $7.51 | 15.4K |
| Sep 11, 2026 | $6.97 | $7.90 | $6.97 | $7.36 | 72.67K |
| Sep 10, 2026 | $7.2644 | $7.29 | $7.0378 | $7.29 | 2.49K |
| Sep 9, 2026 | $7.215 | $7.34 | $7.10 | $7.34 | 4.08K |
| Sep 8, 2026 | $7.32 | $7.33 | $6.96 | $7.33 | 3.17K |
| Sep 4, 2026 | $7.1235 | $7.34 | $6.935 | $7.34 | 1.96K |
| Sep 3, 2026 | $7.165 | $7.17 | $6.90 | $7.17 | 5.56K |
| Sep 2, 2026 | $7.00 | $7.17 | $7.00 | $7.17 | 1.51K |
| Sep 1, 2026 | $6.725 | $7.17 | $6.72 | $7.17 | 2.75K |
| Aug 31, 2026 | $6.80 | $6.98 | $6.80 | $6.98 | 8.55K |
| Aug 28, 2026 | $6.55 | $6.93 | $6.55 | $6.89 | 2.63K |
| Aug 27, 2026 | $6.70 | $6.76 | $6.70 | $6.75 | 3.48K |
| Aug 26, 2026 | $6.79 | $6.79 | $6.65 | $6.70 | 1.92K |
| Aug 25, 2026 | $6.62 | $6.97 | $6.5311 | $6.97 | 2.62K |
| Aug 24, 2026 | $6.44 | $6.90 | $6.44 | $6.81 | 4.7K |
| Aug 21, 2026 | $6.225 | $6.87 | $6.225 | $6.75 | 13.04K |
| Aug 20, 2026 | $6.335 | $6.41 | $6.335 | $6.37 | 3.05K |
| Aug 19, 2026 | $6.50 | $6.50 | $6.00 | $6.42 | 9.11K |
| Aug 18, 2026 | $6.37 | $6.37 | $6.0738 | $6.31 | 8.88K |
| Aug 17, 2026 | $6.66 | $6.72 | $6.498 | $6.58 | 5.87K |
The latest Smart Investors Daily articles mentioning TVGN.
TVGN research
Company profile and research snapshot.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 4, 2026 | D. Boral Capital | Hold | — |
| Mar 3, 2026 | D. Boral Capital | Buy | — |
| Nov 20, 2025 | D. Boral Capital | Buy | — |
| Sep 4, 2025 | D. Boral Capital | Buy | — |
| Aug 18, 2025 | D. Boral Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 29, 2026
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that it will operate under the name Tevogen Inc., following approval by its Board of Directors. The name change reflects
Benzinga · Jun 9, 2026
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced the formation of its healthcare services initiative, a strategic business area intended to support the Company's evolution into a broader,
Benzinga · Mar 13, 2026
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced performance advancements for its artificial intelligence platform, operated through Tevogen.AI.Tevogen.AI was built to solve a critical
Benzinga · Mar 9, 2026
Leadership Designations:Digital Health: Arpita Patel and Wojtek StobinskiGenerics: Sadiq Khan and David BankoContract Research: William KeaneBiotech: Lori GrossoArtificial Intelligence: Mittul Mehta
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TVGN.
